Wedbush Predicts Inozyme Pharma’s Q1 Earnings (NASDAQ:INZY)

Inozyme Pharma, Inc. (NASDAQ:INZY) – Stock analysts at Wedbush issued their Q1 2025 EPS estimates for Inozyme Pharma in a note issued to investors on Monday, March 10th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($0.43) per share for the quarter. Wedbush has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. Wedbush also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.80) EPS.

INZY has been the topic of several other reports. Needham & Company LLC cut their price objective on shares of Inozyme Pharma from $23.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday. Piper Sandler reduced their target price on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Inozyme Pharma in a report on Tuesday. Raymond James reduced their price objective on Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Wells Fargo & Company lowered their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Inozyme Pharma presently has an average rating of “Buy” and a consensus target price of $14.56.

Inozyme Pharma Stock Up 0.0 %

INZY stock opened at $1.00 on Thursday. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The business has a 50 day moving average of $1.44 and a 200 day moving average of $3.23. Inozyme Pharma has a twelve month low of $0.98 and a twelve month high of $7.80. The firm has a market cap of $64.24 million, a PE ratio of -0.64 and a beta of 1.32.

Institutional Investors Weigh In On Inozyme Pharma

Hedge funds have recently modified their holdings of the business. Harvest Investment Services LLC purchased a new position in shares of Inozyme Pharma during the 4th quarter valued at about $31,000. Graham Capital Management L.P. bought a new stake in shares of Inozyme Pharma during the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Inozyme Pharma during the 4th quarter valued at $38,000. D. E. Shaw & Co. Inc. bought a new position in Inozyme Pharma in the 4th quarter worth $49,000. Finally, ProShare Advisors LLC purchased a new stake in Inozyme Pharma in the 4th quarter worth $49,000. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.